{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024106","form_type":"8-K/A","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2023-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.337643+00:00","generated_at":"2026-06-13T10:34:36.789268+00:00","sec_items":["3.02","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Biostage reduces CEO milestone stock options from 488,256 to 267,616 shares","bullets":["Amendment corrects Milestone Grant for CEO Junli He from 488,256 to 267,616 shares.","Each vesting increment reduced from 244,128 to 133,808 shares, still two tranches.","Effective retroactively to March 14, 2023; no other changes to employment agreement.","Reduction lowers potential dilution from milestone options by approximately 45%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024106","json":"https://secwatch.observer/filing/0001493152-23-024106.json","markdown":"https://secwatch.observer/filing/0001493152-23-024106.md","text":"https://secwatch.observer/filing/0001493152-23-024106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223024106/0001493152-23-024106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223024106/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:34:36.789268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}